The Impact of Maternal CMV Infection on Birth Outcomes

先天性巨细胞病毒（CMV）感染是美国出生缺陷和发育障碍的主要原因，每年影响数千名儿童。值得注意的是，大多数儿童获得先天性巨细胞病毒来自非原发母体巨细胞病毒感染，而不是原发感染。因此，在现场确定产妇血清状态可以进一步了解巨细胞病毒感染状态与妊娠结局恶化之间的关系，并在妊娠期间对孕妇进行风险分层。目前检测母体巨细胞病毒血清状态的方法是劳动密集型的，需要复杂的设备、专用的实验室空间和训练有素的技术人员。我们建议开发一种即时护理（POC）测试，用于快速筛查母体巨细胞病毒（CMV）血清状态。生物标本中巨细胞病毒血清状态筛查的快速现场测试将：(1)允许立即咨询和确认测试，(2)避免为生物标本测试创建新的实验室基础设施。另外，在最初的研究筛选访问中使用的快速POC测试将允许有效地识别和登记CMV疫苗测试。

Congenital Cytomegalovirus (CMV) infection is a leading cause of birth defects and developmental disabilities in the U.S., affecting thousands of children each year. Notably, the majority of children acquire congenital CMV from non-primary maternal CMV infection rather than primary infection. Thus, determining the maternal serostatus in the field may further our understanding of the association between CMV infection status and worse pregnancy outcome, and risk stratify pregnant women during gestation. Current methods to detect maternal CMV serostatus are labor intensive and require sophisticated equipment, dedicated laboratory space, and trained technicians. We propose developing a point-of-care (POC) test for rapid screening of maternal CMV serostatus. A rapid, on-site test for CMV serostatus screening in biospecimens would: (1) allow for immediate counseling and confirmatory testing, and (2) avoid having to create new laboratory infrastructure for biospecimen testing. Alternatively, a rapid POC test that could be utilized during initial study screening visits would permit the efficient identification and enrollment for CMV vaccine testing.